Entrada Therapeutics, Inc. (NASDAQ:TRDA) to Post Q2 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Research analysts at HC Wainwright increased their Q2 2024 EPS estimates for shares of Entrada Therapeutics in a report issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.87) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS and FY2025 earnings at ($3.77) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $1.06. Entrada Therapeutics had a net margin of 14.42% and a return on equity of 9.73%. The business had revenue of $59.12 million during the quarter, compared to analyst estimates of $25.00 million.

Entrada Therapeutics Stock Up 0.6 %

Shares of TRDA opened at $14.25 on Thursday. Entrada Therapeutics has a fifty-two week low of $10.75 and a fifty-two week high of $18.44. The company’s fifty day moving average is $14.58 and its two-hundred day moving average is $14.30. The firm has a market cap of $481.08 million, a PE ratio of 22.62 and a beta of -0.23.

Insider Activity at Entrada Therapeutics

In other news, CEO Dipal Doshi sold 1,800 shares of Entrada Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00. Following the sale, the chief executive officer now owns 338,575 shares in the company, valued at $5,078,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Entrada Therapeutics news, Director Peter S. Kim purchased 2,600 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, April 8th. The stock was purchased at an average price of $13.57 per share, with a total value of $35,282.00. Following the completion of the acquisition, the director now owns 62,936 shares of the company’s stock, valued at approximately $854,041.52. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dipal Doshi sold 1,800 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the sale, the chief executive officer now directly owns 338,575 shares of the company’s stock, valued at approximately $5,078,625. The disclosure for this sale can be found here. In the last three months, insiders sold 13,475 shares of company stock worth $205,133. Corporate insiders own 7.58% of the company’s stock.

Institutional Trading of Entrada Therapeutics

Several hedge funds have recently bought and sold shares of the company. New York State Teachers Retirement System acquired a new position in shares of Entrada Therapeutics in the 1st quarter worth approximately $27,000. Acadian Asset Management LLC bought a new stake in Entrada Therapeutics in the first quarter worth $79,000. Tower Research Capital LLC TRC raised its stake in shares of Entrada Therapeutics by 476.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock valued at $87,000 after acquiring an additional 4,777 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Entrada Therapeutics by 27.7% during the 4th quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock worth $177,000 after buying an additional 2,540 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.